Suvretta Capital Management LLC grew its position in shares of Molecular Partners AG (NASDAQ:MOLN - Free Report) by 455.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,221,494 shares of the company's stock after purchasing an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned approximately 5.50% of Molecular Partners worth $10,548,000 at the end of the most recent quarter.
Separately, BVF Inc. IL grew its position in Molecular Partners by 205.5% in the fourth quarter. BVF Inc. IL now owns 1,353,968 shares of the company's stock worth $6,458,000 after acquiring an additional 910,747 shares in the last quarter. 26.55% of the stock is currently owned by hedge funds and other institutional investors.
Molecular Partners Stock Down 0.1%
NASDAQ:MOLN traded down $0.01 during midday trading on Thursday, hitting $3.95. The company had a trading volume of 3,868 shares, compared to its average volume of 20,965. Molecular Partners AG has a 52-week low of $3.36 and a 52-week high of $12.70. The stock's fifty day moving average price is $3.94 and its 200-day moving average price is $4.80. The company has a market capitalization of $159.28 million, a PE ratio of -1.83 and a beta of 1.15.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.11). Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. As a group, research analysts forecast that Molecular Partners AG will post -1.93 earnings per share for the current year.
Analyst Ratings Changes
Separately, Lifesci Capital initiated coverage on shares of Molecular Partners in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $12.00 target price for the company.
Get Our Latest Research Report on Molecular Partners
Molecular Partners Company Profile
(
Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Featured Stories
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
